Prof. Yi Hu 胡毅
Chief Physician, Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Targeted and immunotherapy for lung cancer; neuroendocrine carcinoma treatment; individualized diagnosis and treatment of complex tumors.
Dr. Hu is a Chief Physician and Professor at the First Medical Center of Chinese PLA General Hospital. Dr. Hu holds a doctorate in oncology from Peking Union Medical College and was a visiting scholar at the University of Washington. Dr. Hu has supervised over 40 graduate students and postdoctoral researchers.
Professional roles
- Chair, Molecular Oncology and Immunotherapy Committee, Chinese Research Hospital Association
- Vice Chair, Tumor Immunology and Targeted Therapy Committee, China Medicine Education Association
- Chair, Tumor Immunotherapy Committee, Beijing Breast Disease Prevention and Treatment Society
- Vice Chair, Oncology Committee, Chinese Research Hospital Association
Name order: in Chinese the family name comes first (Hu Yi). Papers usually list the name as Yi Hu or Hu Y.
Selected publications
192 papers on PubMed matched by name and affiliation; 92 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status. PubMed 42864628
- Cancer Commun (Lond), 2026 (senior author): Recruited Monocyte-Derived Macrophages Drive T Cell Inflammation in Immune Checkpoint Inhibitor-Mediated Pneumonitis. PubMed 42688372
- Discov Oncol, 2026 (senior author): Integrative multi-omics analysis identifies a circadian rhythm-associated gene signature for prognosis and therapeutic stratification in lung adenocarcinoma. PubMed 42223738
- Transl Cancer Res, 2026 (senior author): Circadian-immune-related gene signature for lung squamous cell carcinoma: machine learning and multi-omics analysis. PubMed 42305521
- Cancer Immunol Immunother, 2026 (senior author): Hypoalbuminemia induces immunosuppression through disorder in macrophages and drives resistance to immune checkpoint inhibitors. PubMed 41940988
- Cell Immunol, 2026 (senior author): Thymidine induces macrophage M1 polarization in radiation-induced-lung-injury by ATF3/p38 pathway. PubMed 41698309
- BMC Geriatr, 2026 (senior author): Efficacy and safety of immunotherapy in elderly patients with advanced non-small cell lung cancer: a real-world study stratified by age. PubMed 41772472
- Transl Lung Cancer Res, 2026 (senior author): Targeting NLRP3 inflammasome: a novel strategy for improving immune checkpoint inhibitor-associated pneumonitis. PubMed 41808704
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion